Table 3. Characteristics of NY-ESO-1 positive TNBC patients with NY-ESO-1 antibodies.
Patient ID | Age atdiagnosis | Stage | Grade | Recurrence | Status at lastfollow up | Disease free interval in weeks |
1 | 60 | lllA T2 N2 M0 | 3 | NONE, DISEASE FREE | ALIVE | 351 |
2 | 41 | IIA T1 N1 M0 | 3 | NONE, DISEASE FREE | ALIVE | 279 |
3 | 49 | lllC T1 N3 M0 | 3 | NONE, DISEASE FREE | ALIVE | 292 |
4 | 56 | IIA T2 N0 M0 | 3 | NONE, DISEASE FREE | ALIVE | 247 |
5 | 50 | IIA T2 N0 M0 | 3 | NONE, DISEASE FREE | ALIVE | 165 |
6 | 40 | IIB T2 N1 M0 | 3 | NONE, DISEASE FREE | ALIVE | 241 |
7 | 56 | IIA T2 N0 M0 | 3 | NONE, DISEASE FREE | DEAD (pancreas cancer) | 50 |
8 | 39 | IIB T2 N1 M0 | 3 | NONE, DISEASE FREE | ALIVE | 301 |